Large-scale production of embryonic red blood cells from human embryonic stem cells

Olivier, Emmanuel; Qiu, Caihong; Velho, Michelle; Hirsch, Rhoda Elison; Bouhassira, Eric E.

doi:10.1016/j.exphem.2006.07.003

Cited by 147 publications

(133 citation statements)

References 33 publications

(34 reference statements)

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…During erythropoiesis from hESCs and hiPSCs, the major globin forms are embryonic « and fetal g; little adult b-globin is expressed [7], indicating incomplete globin switching. Why the switching is not accomplished remains unclear, however [8][9][10][11][12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Multicolor Staining of Globin Subtypes Reveals Impaired Globin Switching During Erythropoiesis in Human Pluripotent Stem Cells

Ochi

Takayama

Hirose

et al. 2014

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Adult hemoglobin composed of a-and b-globin reflects a change from expression of embryonic «-and fetal g-globin to adult b-globin in human erythroid cells, so-called globin switching. Human pluripotent stem cells (hPSCs) are a potential source for in vitro erythrocyte production, but they show prominent expression of g-globin with little b-globin expression, which indicates incomplete globin switching. To examine the mechanism of this impaired globin switching, we optimized multicolor flow cytometry to simultaneously follow expression of different globin subtypes using different immunofluorescent probes. This enabled us to detect upregulation of b-globin and the corresponding silencing of g-globin at the single-cell level during cord blood CD34 + cell-derived erythropoiesis, examined as an endogenous control. Using this approach, we initially characterized the heterogeneous b-globin expression in erythroblasts from several hPSC clones and confirmed the predominant expression of g-globin. These hPSC-derived erythroid cells also displayed reduced expression of BCL11A-L. However, doxycycline-induced overexpression of BCL11A-L in selected hPSCs promoted g-globin silencing. These results strongly suggest that impaired g-globin silencing is associated with downregulated BCL11A-L in hPSC-derived erythroblasts and that multicolor staining of globin subtypes is an effective approach to studying globin switching in vitro. STEM CELLS TRANSLATIONAL MEDICINE 2014;3:792-800

show abstract

Section: Introductionmentioning

confidence: 99%

Multicolor Staining of Globin Subtypes Reveals Impaired Globin Switching During Erythropoiesis in Human Pluripotent Stem Cells

Ochi

Takayama

Hirose

et al. 2014

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…hESC-derived mature erythrocytes with a universal blood type such as blood group O and suppressed expression of HLA molecules will be an ideal source of erythrocytes in transfusions. Large-scale productions of mature erythroid cells from hESCs have recently been reported by several groups, including ours (F. Ma, et al 2008a; SJ Lu, et al 2008;EN. Olivier, et al 2006).…”

Section: Generation Of Blood Cells From Human Embryonic Stem Cells Anmentioning

confidence: 99%

Generation of Blood Cells from Human Embryonic Stem Cells and Their Possible Clinical Utilization

Ma¹,

Yang²,

Ebihara³

et al. 2011

Embryonic Stem Cells - Recent Advances in Pluripotent Stem Cell-Based Regenerative Medicine

View full text Add to dashboard Cite

“…To this end, with the availability of hiPSCs, the next step of obtaining HSCs/HPCs from hiPSCs can now be achieved. Since various hematopoietic-derived cell types have been successfully induced from human ESCs (hESCs), including red blood cells, [13][14][15][16] monocytes, 17 dendritic cells (DCs), 18 megakaryocytes 19 and lymphocytes, 20 it is anticipated that hiPSCs can also differentiate into hematopoietic cells using similar methods previously applied to hESCs.…”

Section: Ipscs Can Redifferentiate Into To Hscsmentioning

confidence: 99%

Induced pluripotent stem cell (iPSCs) and their application in immunotherapy

2013

View full text Add to dashboard Cite

The ever-improving technology to generate induced pluripotent stem cells (iPSCs) has increased their potential use as novel candidates for disease modeling, drug screening, regenerative medicine and cell therapy. Indeed, iPSCs offer extensive capacity for self-renewal without the ethical concerns faced by embryonic stem cells (ESCs). With respect to potential applications in the immune system, many studies provide evidence to support that there are exclusive advantages to using iPSCs over other systems. Both hematopoietic stem cells and several types of mature immune cells have successfully been reprogrammed to iPSCs and vice versa, paving a path toward our ability to effectively model patient-specific diseases and provide potentially alternative cell sources for transfusion medicine. Despite these potential advances, some limitations regarding the use of iPSCs in the clinic still remain, including the immunogenicity of iPSCs and their derivatives, which is currently under debate in the field. In this review, we mainly focus on discussing the recent progress being made in the latest differentiation methods and clinical implications of iPSCs with respect to the immune system. Additionally, current issues regarding the clinical application of iPSCs are addressed, especially the controversy surrounding immunogenicity, along with various other perspectives.

show abstract

Large-scale production of embryonic red blood cells from human embryonic stem cells

Cited by 147 publications

References 33 publications

Multicolor Staining of Globin Subtypes Reveals Impaired Globin Switching During Erythropoiesis in Human Pluripotent Stem Cells

Multicolor Staining of Globin Subtypes Reveals Impaired Globin Switching During Erythropoiesis in Human Pluripotent Stem Cells

Generation of Blood Cells from Human Embryonic Stem Cells and Their Possible Clinical Utilization

Induced pluripotent stem cell (iPSCs) and their application in immunotherapy

Contact Info

Product

Resources

About